Acute methoxetamine poisoning - Case report;Ostre zatrucie m etoksetamina̧ - Opis przypadku

Problems of Forensic Sciences

Volumn 91, Issue , 2012, Pages 235-242

  Hydzik, Piotr ^a,b   Gomółka, Ewa ^a,b   Sulka, Adrianna ^a,b   Cudzich Czop, Sylwia ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

HPLC; Methoxetamine; Poisoning

Indexed keywords

BENZODIAZEPINE; KETAMINE; METHOXETAMINE; UNCLASSIFIED DRUG;

ADULT; ARTERIAL PRESSURE; ARTICLE; CASE REPORT; CLINICAL FEATURE; DROWSINESS; DRUG INTOXICATION; DRUG OVERDOSE; DYSPHAGIA; HALLUCINATION; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METHOXETAMINE POISONING; MOTOR DYSFUNCTION;

EID: 84870921149     PISSN: 12307483     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Byrska B., Zuba D., Application of fast gas chromatography to routine analysis of narcotic drugs and psychotropic substances, Problems of Forensic Sciences 2009, 79, 303-313.
2. Corazza O., Schifano F., Simonato P. [et al.], Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine, Human Psychopharmacology 2012, 27, 145-149.
3. Covvey J. R., Crawford A. N., Lowe D. K., Intravenous ketamine for treatment-resistant major depressive disorder, The Annals of Pharmacotherapy 2012, 46, 17-23.
4. Gibbons S., "Legal highs" - novel and emerging psychoactive drugs: a chemical overview for the toxicologist, Clinical Toxicology (Philadelphia) 2012, 50, 15-24.
5. Haroz R., Greenberg M. I., New drugs of abuse in North America, Clinics in Laboratory Medicine 2006, 26, 147-164.
6. Hays P. A, Casale J. F., Berrier A. L., The characterization of 2-(3-Methoxyphenyl)-2-(ethylamino)cyclohe xanone (Methoxetamine), Microgram Journal 2012, 9, 3-17.
7. Hofer K. E., Grager B., Müller D. M. [et al.], Ketamine-like effects after recreational use of methoxetamine, Annals of Emergency Medicine 2012, Jan 9.
8. Mathew S. J., Shah A., Lapidus K. [et al.], Ketamine for treatment-resistant unipolar depression: current evidence, CNS Drugs 2012, 26, 189-204.
9. Murrough J. W., Ketamine as a novel antidepressant: from synapse to behavior, Clinical Pharmacology and Therapeutics 2012, 91, 303-309.
10. POISINDEX, Micromedex Health Care System v. 2.00, Thomson Micromedex 2012.
11. Rosenbaum C. D., Carreiro S. P., Babu K. M., Here today, gone tomorrow... and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines, Journal of Medical Toxicology 2012, 8, 15-32.
12. Shields J. E., Dargan P. I., Wood D. M. [et al.], Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation, Clinical Toxicology (Philadelphia) 2012, 50, 438-440.
13. Ward J., Rhyee S., Plansky J. [et al.], Methoxetamine: a novel ketamine analog and growing health-care concern, Clinical Toxicology (Philadelphia) 2011, 49, 874-875.
14. Wood D. M., Davies S., Puchnarewicz M. [et al.], Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine, European Journal of Clinical Pharmacology 2012, 68, 853-856.